The 50 most recent market catalysts affecting $JNJ, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Bullish
Impact 65
Anvisa Approves Johnson & Johnson's ICOTYDE® (icotroquinra) for Plaque Psoriasis
Johnson & Johnson announced that Anvisa has approved ICOTYDE® (icotroquinra) for the treatment of moderate-to-severe plaque psoriasis. This is a significant development as it intro…
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 75
Blackstone Life Sciences Announces $750 Million R&D Funding Agreement with Johnson & Johnson
Blackstone Life Sciences has committed $750 million to fund the Phase 3 clinical development of OLN324, a therapy for retinal vascular diseases, for Johnson & Johnson. This signifi…
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 95
Johnson & Johnson to Acquire Ollin Biosciences for Up to $3.4 Billion
Johnson & Johnson is acquiring Ollin Biosciences for up to $3.4 billion, a strategic move to expand its pharmaceutical or medical technology portfolio. This acquisition is signific…
Nov 10, 2026
Corporate Catalyst
Bearish
Impact 65
California Jury Awards $34.21 Million in Talc-Asbestos Mesothelioma Case
A California jury found Johnson & Johnson liable for $34.21 million in a mesothelioma case, attributing 40% of the responsibility to the company for failing to warn about asbestos …
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson Announces Positive Results from Second Phase 3 Study of CAPLYTA for Bipolar Mania
Johnson & Johnson announced that its second pivotal Phase 3 study for CAPLYTA in treating bipolar mania successfully met its primary and key secondary endpoints. This is significan…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 55
Johnson & Johnson's JJDC Participates in $100M Financing for Delix Therapeutics
Johnson & Johnson's venture capital arm, JJDC, invested in Delix Therapeutics' $100 million funding round. This move signifies J&J's ongoing strategic interest in the mental health…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 65
Johnson & Johnson Reports Phase 1 Results for Investigational Prostate Cancer Combination
Johnson & Johnson reported encouraging Phase 1 results for its novel bispecific antibody combination, pasritamig and JNJ-9401, in advanced prostate cancer. The 73% PSA response rat…
Nov 8, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson Reports Positive Phase 3 Results for ICOTYDE in Psoriatic Arthritis
Johnson & Johnson reported that its Phase 3 study for ICOTYDE in psoriatic arthritis met its primary endpoint, showing a 58% ACR20 response rate compared to 41% for placebo. This p…
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Grants Accelerated Approval for RYBREVANT FASPRO in Head and Neck Squamous Cell Carcinoma
Johnson & Johnson announced that its drug RYBREVANT FASPRO received accelerated FDA approval for a new indication: recurrent or metastatic head and neck squamous cell carcinoma in …
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 65
Johnson & Johnson Receives NMPA Approval for Macitentan Dispersible Tablets
Johnson & Johnson (JNJ) has received NMPA approval in China for its macitentan dispersible tablets, targeting pediatric pulmonary arterial hypertension. This is a positive developm…
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 55
Johnson & Johnson Reports Positive Clinical Outcomes for Impella Heart Pumps in HRPCI
Johnson & Johnson (JNJ) reported positive clinical outcomes for its Impella heart pumps, used in high-risk percutaneous coronary intervention (HRPCI), based on data presented at TC…
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 65
Johnson & Johnson Reports Positive Clinical Trial Results for Shockwave Javelin Catheter
Johnson & Johnson reported positive 30-day results from its FORWARD CAD study for the Shockwave Javelin catheter, an investigational device designed to treat severely narrowed coro…
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 65
Spherix Global Insights Report on Johnson & Johnson's Icotyde Market Performance
Spherix Global Insights reported that Johnson & Johnson's Icotyde is gaining traction in the U.S. plaque psoriasis market, driven by strong efficacy and physician confidence. This …
Oct 27, 2026
Corporate Catalyst
Neutral
Impact 55
Johnson & Johnson to Host Enterprise Business Review
Johnson & Johnson has scheduled an Enterprise Business Review for December 8, 2026. During this event, company leadership will provide a detailed look into its Innovative Medicine …
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 65
Johnson & Johnson Reports Phase 1b/2 Results for Subcutaneous Amivantamab in Head and Neck Cancer
Johnson & Johnson reported encouraging Phase 1b/2 results for its drug amivantamab in combination with other treatments for recurrent or metastatic head and neck squamous cell carc…
Oct 25, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson Reports Positive Phase 1 Results for JNJ-6143 in Advanced Prostate Cancer
Johnson & Johnson reported encouraging Phase 1 results for JNJ-6143, an investigational drug for advanced prostate cancer, demonstrating a 75% tumor response rate. This is a signif…
Oct 24, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson Announces Positive Phase 3 PROTEUS Substudy Results for Prostate Cancer Treatment
Johnson & Johnson announced highly positive results from a Phase 3 PROTEUS substudy for its prostate cancer treatment, apalutamide combined with ADT. The regimen significantly redu…
Oct 23, 2026
Corporate Catalyst
Bullish
Impact 65
European Commission Approves TECVAYLI® Indication Extension for Multiple Myeloma
Johnson & Johnson received European Commission approval for an expanded indication of its drug TECVAYLI® (teclistamab) for relapsed/refractory multiple myeloma. This approval allow…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 55
Johnson & Johnson Named Strategic Enterprise by Hong Kong's OASES
Johnson & Johnson has been selected as a Strategic Enterprise by Hong Kong's OASES, indicating a strengthened commitment to the region. This partnership is significant as it aims t…
Oct 21, 2026
Corporate Catalyst
Bearish
Impact 55
Erste Group Downgrades Johnson & Johnson to Hold
Erste Group has downgraded Johnson & Johnson's stock rating to 'Hold'. This move signifies a more cautious stance from the investment firm regarding JNJ's future performance, sugge…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 65
Johnson & Johnson Announces 1-Yr Results From Phase 3 FUZION Study Showing TREMFYA Maintained Or Improved Fistula Remission Through 48 Weeks In Adults With Crohn's Disease
Johnson & Johnson announced one-year results from its Phase 3 FUZION study for TREMFYA, indicating the drug maintained or improved fistula remission in adults with Crohn's disease …
Oct 16, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $287
Wells Fargo analyst Larry Biegelsen has maintained an 'Overweight' rating on Johnson & Johnson (JNJ) and raised the price target from $275 to $287. This action signals continued co…
Oct 14, 2026
Corporate Catalyst
Bearish
Impact 75
Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts
Johnson & Johnson's Q3 results showed an earnings beat and raised guidance, yet its shares experienced a sell-off, leading analysts to cut price targets. This 'excessive' sell-off,…
Oct 14, 2026
Corporate Catalyst
Bearish
Impact 75
These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results
Johnson & Johnson (JNJ) delivered a robust third quarter, exceeding analyst expectations for both top and bottom lines and subsequently increasing its full-year financial outlook. …
Oct 14, 2026
Corporate Catalyst
Bearish
Impact 55
Wells Fargo Maintains Overweight on Johnson & Johnson, Lowers Price Target to $275
Wells Fargo analyst Larry Biegelsen maintained an 'Overweight' rating on Johnson & Johnson, signaling continued confidence in the company's long-term prospects. However, the price …
Oct 14, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Johnson & Johnson, Lowers Price Target to $280
RBC Capital's analyst Trung Huynh reiterated an 'Outperform' rating for Johnson & Johnson, signaling continued confidence in the company's long-term prospects. However, the price t…
Oct 14, 2026
Market Technicals
Bearish
Impact 55
Stock of the Day: Is this the Bottom for Johnson & Johnson?
Johnson & Johnson's stock experienced a significant drop after its earnings report, leading to speculation about a potential bottom. This filing focuses on a technical analysis, id…
Oct 13, 2026
Corporate Catalyst
Bearish
Impact 92
QUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss
Johnson & Johnson's stock is facing its steepest one-day drop since April 2025, despite beating profit estimates and raising its full-year forecast. The primary catalyst for this n…
Oct 13, 2026
Corporate Catalyst
Neutral
Impact 65
'J&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business' - The Wall Street Journal
Johnson & Johnson is reportedly exploring a spin-off of its orthopedic hips-and-knees business, following its successful Kenvue consumer health spin-off. This strategic move aims t…
Oct 13, 2026
Corporate Catalyst
Bullish
Impact 85
Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)
Johnson & Johnson delivered a strong Q3 2026 performance, exceeding Wall Street expectations for both sales and adjusted earnings, and subsequently raised its full-year 2026 guidan…
Oct 13, 2026
Corporate Catalyst
Bearish
Impact 85
Johnson & Johnson shares are trading lower after the company reported Q3 financial results and raised its FY26 sales guidance with its midpoint below estimates.
The primary impact is negative for Johnson & Johnson (JNJ) as the market is reacting to the future sales guidance being below estimates, even though Q3 results were reported. This …
Oct 13, 2026
Corporate Catalyst
Neutral
Impact 92
Transcript: Johnson & Johnson Q3 2026 Earnings Conference Call
Johnson & Johnson (JNJ) announced strong third-quarter 2026 earnings, with operational sales growth of 6% and revenues exceeding $25 billion. This performance led the company to ra…
Oct 13, 2026
Corporate Catalyst
Neutral
Impact 75
Johnson & Johnson Says Q3 Reflects One-Time Special Charge for Proposed Talc Litigation Resolution, Acquisition of Firefly Bio, And Strategic Collaboration With Sail Biomedicines
This headline indicates a mixed bag for Johnson & Johnson. The 'one-time special charge' for talc litigation will negatively impact Q3 earnings, but its 'one-time' nature suggests …
Oct 12, 2026
Corporate Catalyst
Bullish
Impact 65
Johnson & Johnson Announces Three-Year Data From Its Phase 3 GALAXI 2, 3 Trials Of TREMFYA Demonstrate Efficacy, Consistent Profile To Treat Crohn's Disease
Johnson & Johnson released three-year data from its Phase 3 GALAXI 2 and 3 trials for TREMFYA (guselkumab) in moderately to severely active Crohn's disease. The data, to be present…
Oct 9, 2026
Corporate Catalyst
Bullish
Impact 55
Johnson & Johnson Announces New Two-year Results From Its Phase 3 ICONIC-LEAD Study Evaluating ICOTYDE In Adults With Moderate-To-Severe Plaque Psoriasis; Data Demonstrated Consistently High Levels Of Skin Clearance And Patient-Reported Symptom Improvement At Week 112, With No New Safety Signals
Johnson & Johnson released two-year data from its Phase 3 ICONIC-LEAD study for ICOTYDE, a treatment for moderate-to-severe plaque psoriasis. The results showed sustained high leve…
Sep 30, 2026
Corporate Catalyst
Neutral
Impact 65
Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
This filing details analyst sentiment and financial forecasts for Johnson & Johnson (JNJ) leading up to its Q3 earnings report. Several 'most accurate' analysts have recently raise…
Sep 29, 2026
Corporate Catalyst
Bearish
Impact 75
Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss
This filing discloses an analyst's pre-earnings preview for Johnson & Johnson's Q3 2027 results. The key takeaway is the expectation of an earnings miss, driven by significant IPR&…
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 65
Johnson & Johnson To Present New Findings On IMAAVY For Treatment Of Generalized Myasthenia Gravis Across 15 Novel Abstracts At 2026 MGFA Scientific Session And AANEM Annual Meeting
Johnson & Johnson is announcing new, positive two-year clinical trial data for its drug IMAAVY in treating generalized myasthenia gravis (gMG) in adolescents. The findings show sus…
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 65
Johnson & Johnson Announces That TREMFYA Met Primary And Major Secondary Endpoints Demonstrating Both Improvement In Axial Symptoms And Reduction In Inflammation By MRI Assessment In The Phase 4 STAR Study Evaluating Biologic-Naïve Adults With Active Psoriatic Arthritis And Axial Involvement
Johnson & Johnson's TREMFYA, an IL-23 inhibitor, successfully met its primary and major secondary endpoints in the Phase 4 STAR study for axial psoriatic arthritis. This is signifi…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson Announces Data From Phase 3 MajesTEC-3 Trial Demonstrates Disease Control, Survival With TECVAYLI Plus DARZALEX FASPRO To Treat Relapsed Or Refractory Multiple Myeloma
Johnson & Johnson announced new data from its Phase 3 MajesTEC-3 study, showing that the combination of TECVAYLI and DARZALEX FASPRO achieved sustained disease control and survival…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 65
Johnson & Johnson Drug Shows Improved Mania Symptoms in Bipolar Patients
Johnson & Johnson reported positive topline results from a Phase 3 study for Caplyta (lumateperone), showing significant and rapid improvement in manic symptoms for adults with bip…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson Announces CAPLYTA Demonstrates Reduction In Signs, Symptoms Of Acute Manic Episodes Associated With Bipolar I Disorder In Phase 3 Trial
Johnson & Johnson announced positive topline results from a pivotal Phase 3 study for CAPLYTA (lumateperone) in treating manic episodes associated with bipolar I disorder. This is …
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival
Johnson & Johnson released new clinical data for its lung cancer drug, RYBREVANT FASPRO, from two studies. The COPERNICUS study showed a better safety profile with fewer discontinu…
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 65
Reported Earlier, J&J's Subcutaneous RYBREVANT FASPRO Plus LAZCLUZE Shows Lower Rash, Administration-Related Reaction, Venous Thromboembolism Rates Than Intravenous MARIPOSA Regimen
Johnson & Johnson (JNJ) released new clinical data for its subcutaneous RYBREVANT FASPRO plus LAZCLUZE combination, showing significantly lower rates of adverse events like rash, b…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson’s RYBREVANT Combination Extends Survival To 34.3 Months In EGFR Exon 20+ Lung Cancer
Johnson & Johnson announced compelling new data for its drug RYBREVANT (amivantamab-vmjw) when combined with chemotherapy, showing a median overall survival of 34.3 months in patie…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, Johnson & Johnson Says Rybrevant Plus Chemotherapy Cuts Risk Of Death By 43% Versus Chemotherapy Alone When Adjusted For Crossover In Final PAPILLON Overall Survival Analysis
Johnson & Johnson reported final overall survival analysis data for its drug Rybrevant, showing a 43% reduction in the risk of death when combined with chemotherapy for a specific …
Sep 10, 2026
Market Technicals
Bullish
Impact 55
HSBC Maintains Buy on Johnson & Johnson, Raises Price Target to $320
HSBC analyst Rajesh Kumar maintained a 'Buy' rating on Johnson & Johnson and raised the price target from $290 to $320. This action signals increased confidence from the analyst in…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 55
Johnson & Johnson Receives CE Marking For ACUVUE OASYS MAX 2-Week, New Reusable Contact Lens Featuring Proprietary MAX Technologies To Deliver Lasting Comfort And Clear Vision, Even At Day 14
Johnson & Johnson has secured CE Marking for its ACUVUE OASYS MAX 2-Week contact lens, a crucial regulatory approval for the European market. This allows J&J to introduce a new, ad…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.